Alexion continues rare disease M&A with Syntimmune acquisition
Alexion has agreed to pay up to $1.2bn for Syntimmune and its lead asset SNT001, a monoclonal antibody designed to treat warm autoimmune haemolytic anaemia.
Archives for October 3, 2018
Biologics access threatened by US-Mexico-Canada agreement, says biosimilar industry
The US, Mexico and Canada have agreed a trade deal that includes 10 years of data protection for biologics.
Regeneron and Sanofi receives first US FDA approval for PD-1 treatment
The US FDA approved the first drug created by the 2015 partnership between Regeneron and Sanofi to research and develop immuno-oncology therapies.